Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Abroad (travel likely)CompletedPHASE1
Conditions
Advanced Solid Tumors
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
The Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Study leads
Crystal Denlinger, MD
Principal Investigator
Fox Chase Cancer Center
Kwok Kin Wong, MD
Principal Investigator
Dana-Farber Cancer Institute
Keedy L Vicki, MD
Principal Investigator
Vanderbilt University Medical Center